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Context: Two tyrosine kinase inhibitors (TKIs), lenvatinib and vandetanib, are often used to treat
advanced radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) and medullary thyroid
cancer (MTC), respectively. Fatigue is a common adverse event during treatment with these and
other TKIs and a common cause of drug discontinuation or dosage reduction.
Cases Description: We evaluated the basal and stimulated adrenal function in 12 patients with
advanced RAI-R DTC and MTC treated with lenvatinib or vandetanib, respectively. Ten patients
complaining of fatigue showed a progressive ACTH increase with normal cortisol levels.
Moreover, six of 10 patients had a blunted cortisol response after ACTH stimulation, thus
confirming the diagnosis of primary adrenal insufficiency (PAI). The causal relationship
between TKIs and PAI onset was also demonstrated by the repeated testing of adrenal
function before and during treatment. Patients with PAI received cortisone acetate
replacement therapy, with a substantial and prompt improvement in the degree of fatigue,
as assessed by the Common Terminology Criteria for Adverse Events version 4.03, thus
supporting the major impact of impaired adrenal function in the genesis of this adverse event.
Conclusions: We show that the occurrence of PAI may be a common cause of fatigue during
lenvatinib and vandetanib treatment, and we therefore recommend testing adrenal function for a
prompt start of replacement therapy to avoid treatment discontinuation, dosage reduction, and
potentially severe PAI complications. (J Clin Endocrinol Metab 104: 779–784, 2019)
Two tyrosine kinase inhibitors (TKIs), lenvatinib andvandetanib, are often used to treat advanced
radioiodine-refractory differentiated thyroid cancer
(RAI-R DTC) and medullary thyroid cancer (MTC),
respectively. Lenvatinib inhibits both angiogenesis, act-
ing on VEGFR 1-3, FGFR 1-4, and PDGFR a, and
carcinogenesis, acting on RET and c-KIT. Vandetanib
works on VEGFR 1-3 and EGF-R and on RET, which is
the oncogene responsible for MTC. Several adverse
events (AEs) have been reported in almost all treated
patients, largely overlapping between the two com-
pounds and including hypertension, fatigue, diarrhea,
and weight loss. They led to treatment discontinuation in
14.2% of patients on lenvatinib (SELECT study) and
12% of patients on vandetanib (ZETA study). Un-
explained fatigue or asthenia is present in 59% and 24%
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of patients treated with lenvatinib and vandetanib, re-
spectively, and it is one of the most common causes of
treatment discontinuation (1, 2). Despite recommenda-
tions to have patients to take TKIs in the evening and do
physical exercise, to monitor electrolytes and TSH levels,
and to maintain hydration and adequate food intake (3),
in most cases the symptom persists and dosage reductions
are needed.
Information on adrenal function during TKI treatment
is scanty. An increased prevalence of subclinical hypo-
cortisolism in patients on imatinib was reported (4),
whereas an elevation of cortisol was found in 14 patients
treated with vandetanib, although the possible diagnosis
of hypercortisolism was ruled out by the free urinary
cortisol in the lower part of normal range (5).
Methods
After obtaining written informed consent, we evaluated 12
consecutive patients with advanced RAI-R DTC and MTC
during treatment with lenvatinib (n = 7) and vandetanib (n = 5)
and followed up at a single institution. The clinical features
of the patients are reported in Table 1. Fatigue was assessed
by the Common Terminology Criteria for Adverse Events
(CTCAE) version 4.03. None of the patients complained of
fatigue before the start of lenvatinib treatment (grade 0).
We performed in all patients, at different stages of
treatment, a basal evaluation of adrenal function during the
morning (8:00 to 9:00 AM) and in a fasting state. Patients on
cortisone acetate (CA) always received the treatment after
blood sampling. Serum and urinary free cortisol and ACTH
were assayed with the Elecsys® cortisol and ACTH im-
munoassays (Roche Diagnostics, Mannheim, Germany).
All patients also underwent a 250-mg ACTH stimulation
test, which is considered the gold standard to establish the
diagnosis of primary adrenal insufficiency (PAI) (6). The
morning of the ACTH test, we assessed at baseline salivary
cortisol, 24-hour urinary free cortisol, and adrenal au-
toantibodies. Salivary cortisol was assayed with liquid
chromatography–tandem mass spectrometry with the Wa-
ters Xevo TQ MS system (Waters, Milford, MA; normal
values .0.265 mg/dL), and adrenal autoantibodies were
determined by an indirect immunofluorescence assay with
precoated primate adrenal slides (Astra Formedic, Lessolo,
Italy). Only in patient 7 was adrenal function evaluated before
the start of TKI treatment.
Results
Ten out of the 12 treated patients complained of fatigue
(six on lenvatinib and four on vandetanib). Only these
10 patients showed a progressive increase in ACTH levels
with normal cortisol concentrations, a combination of
findings consistent with incipient PAI (Fig. 1A). In patient
7, ACTH levels rose from 20 ng/L at baseline to 100 ng/L
during the first months of lenvatinib treatment. The
24-hour urinary free cortisol levels were in the lower part
of the normal range in all patients (39.73 6 6.0 mg,
normal levels 17.0 to 136.0 mg); mean morning salivary
cortisol levels were 0.316 0.08 mg/dL, below the normal
Table 1. Clinical Features of the Patients Treated With Lenvatinib and Vandetanib
Patient/Sex
Age at
Diagnosis/Age
at TKI Start (y)
Tumor
Histotype
TNM/AJCC
Stage
ECOG
Status Treatment (Dose, mo) Adverse Events (Grade)a
Disease
Status
1/F 63/74 PDTC pT3NXM0/II 1 Lenvatinib (20 → 10 mg, 21) Hypertension (3), fatigue (2), diarrhea (1), weight loss (1),
anorexia (1), proteinuria (2), reversible posterior
leukoencephalopathy (3)
PR
2/F 42/58 FTC pT2NXM0/I 0 Lenvatinib (20 mg, 21) Hypertension (3), fatigue (2), diarrhea (2), anorexia (1),
palmar-plantar erythrodysesthesia syndrome (1),
stomatitis (1), hemorrhoids (3)
SD
3/M 51/58 PTC Tall cell pT4aN1aM0/ I 0 Lenvatinib (24 mg, 13) Fatigue (2), diarrhea (1), weight loss (1), anorexia (1),
proteinuria (1), palmar-plantar erythrodysesthesia
syndrome (1)
PR
4/F 33/75 CPTC N/A 1 Lenvatinib (10 mg, 13) Hypertension (3), fatigue (1), diarrhea (2), stomatitis (3),
nausea (1), hemorrhoids (2)
PR
5/F 71/72 CPTC pT3NXM0/II 1 Lenvatinib (10 mg, 15) Hypertension (2), fatigue (2), diarrhea (2), anorexia (1),
skin ulceration (2), arthralgia (1), hoarseness (1),
dysgeusia (1)
PR
6/M 67/68 FTC pT4bNXM1/IVb 0 Lenvatinib (20 mg, 9) Hypertension (3), stomatitis (2), dysgeusia (1) SD
7/M 54/66 CPTC pT4aN1MX/I 0 Lenvatinib (20 mg, 5) Fatigue (2), weight loss (1), hypertension (3), anorexia (1) N/A
8/M 46/63 sMTC pT4N1bM1/II 1 Vandetanib (100 mg, 44) Fatigue (2), diarrhea (3), anorexia (1) SD
9/F 8/9 MEN2B pT4aN1b/II 0 Vandetanib (200 mg, 118) Fatigue (2), weight loss (1) SD
10/M 9/20 MEN2B N/A 0 Vandetanib (300 → 150 →
100 mg, 43)
Fatigue (1), diarrhea (1), QTc prolongation (2) SD
11/F 21/28 sMTC pT3N1bM1/II 0 Vandetanib (300 mg, 10) Fatigue (2), diarrhea (1), maculopapular rash (1) PR
12/F 72/76 sMTC pT2N1b/II 1 Vandetanib (300 → 150 →
100 mg, 36)
Anorexia (1), QTc prolongation (2) PR
Required dosage reductions are reported.
Abbreviations: AJCC, American Joint Committee on Cancer; CPTC, papillary thyroid cancer classic variant; F, female; FTC, follicular thyroid cancer; M,
male; MEN2B, multiple endocrine neoplasia 2B; N/A, not available; PDTC, poorly differentiated thyroid cancer; PR, partial response; PTC, papillary thyroid
cancer; SD, stable disease; sMTC, sporadic MTC; TKI, tyrosine kinase inhibitors; TNM, tumor size, lymph nodes affected, metastases.
aSeverity grade was measured according to the CTCAE, version 4.03; the degree of fatigue reported is intended before the start of CA treatment.
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range in six of 10 patients, and adrenal autoantibodies
were negative in all patients (Table 2). Moreover, six
of the 10 patients complaining of fatigue showed an
impaired response of cortisol upon ACTH infusion,
thus confirming the PAI diagnosis (Fig. 1B) (6). Inter-
estingly, patient 3 experienced an adrenal crisis imme-
diately after the ACTH test, with prompt resolution
upon hydrocortisone administration, further supporting
the diagnosis of adrenal insufficiency. Whole body
CT or whole body fluorine-18–2-fluoro-2-deoxy-D-
glucose positron emission tomography and abdominal
ultrasound ruled out adrenal metastases or adrenal gland
alterations in all cases. Hepatic and renal functions,
glycemia, and hemoglobin were in the normal range in all
cases, and none of the patients was on treatment with
drugs potentially leading to fatigue (e.g., antipsy-
chotics). Renin and aldosterone were not measured
because all patients were on interfering antihyper-
tensive treatment because of a known TKI side effect.
Nevertheless, the finding of normal electrolyte levels
in all patients is consistent with conserved mineral-
ocorticoid function. In patients with RAI-R DTC,
Figure 1. (A) Cortisol (mg/dL) and ACTH (ng/L) levels in the patients treated with lenvatinib (n = 7) and vandetanib (n = 5) according to
treatment duration. In particular, the first adrenal function evaluation and the last assessment before the start of cortisone acetate replacement
are reported. Interestingly, for patient 7, the evaluation of adrenal function was available before the start of the lenvatinib treatment (asterisk),
and the two following evaluations without cortisone acetate therapy are also reported. The lowest normal cortisol level (5 mg/dL) and the highest
normal ACTH level (50 ng/mL) are reported in the figure. (B) Cortisol levels at baseline and at 30, 60, and 90 minutes after infusion of 250 mmg
ACTH in the 12 patients. CA replacement treatment was started in patients 1, 2, 3, 7, 9, and 11. Peak cortisol levels ,500 nmol/L (18 mg/dL,
dotted line) at 30 or 60 minutes indicate adrenal insufficiency.
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L-thyroxine dosage was titrated to maintain TSH
levels below the normal limit (0.01 to 0.1 mU/L),
either before or during lenvatinib treatment. In pa-
tients with advanced MTC, TSH levels were in the
normal range (0.5 to 2 mU/L). No significant corre-
lation between TKI dosage and the degree of fatigue
was observed (data not shown). Patients with fatigue
grade 2 and those with an established diagnosis of PAI
(1, 2, 3, 7, 9, and 11) received CA replacement at the
standard dosage (25 to 35 mg/day). All patients but 1
reported substantial improvements in fatigue imme-
diately after the first days of treatment (to grade 1 or 0
in three or two cases, respectively). No symptom relief
was reported by patient 1, who had cortisol levels
stably in the high normal range (Fig. 2A). This patient
developed minor depression during TKI treatment, and
it is likely that the related manifestations could have
masked the beneficial effects of CA replacement. As
in typical patients with PAI, ACTH levels remained
elevated during replacement treatment (Fig. 2B),
and the CA dosage was adjusted based on clinical
response (6).
Discussion
These data show the frequent occurrence of PAI after the
first months of treatment with lenvatinib or vandetanib
in patients with advanced RAI-R DTC or MTC. PAI is
a likely cause of the chronic severe fatigue reported
by several patients and may represent a life-threatening
condition under stress. Importantly, replacement treat-
ment with CA is associated with substantial relief of this
major adverse event. Because assessment of the adequacy
of replacement with glucocorticoids cannot rely on
morning ACTH levels, fine-tuning of daily cortisone
acetate dosage should be done only through a careful and
complete clinical assessment, including evaluation of
fatigue (7).
Adrenal toxicity, represented as cortical hemorrhage
or necrosis, was seen in rats and monkeys treated with
sunitinib (8), possibly because of the reduced density of
capillary networks seen in some endocrine organs upon
administration of anti-VEGF compounds (9, 10). Al-
though anti-VEGF treatments often lead to the devel-
opment of hypothyroidism in mice (10) and humans,
scanty and controversial data are available on adrenal
function (4, 5), probably because of the existence of
compensatory mechanisms or misdiagnosis. Indeed,
thyroid function is always evaluated during TKI ad-
ministration, but adrenal function testing is not recom-
mended. Our data strongly suggest that appropriate
testing of adrenal function should be included in the
follow-up of patients treated with lenvatinib or vande-
tanib to prevent the onset or worsening of fatigue and
other severe consequences of PAI. The limitations of our
study include the limited number of subjects, the lack of
evaluation of adrenal function before TKI began in all
patients, and the lack of a control group. Nevertheless,
although for most patients adrenal function was tested at
various times after the start of TKI treatment, a clear
causal relationship between TKI and PAI onset was seen
in patient 7, whose adrenal function was repeatedly
tested before and during lenvatinib treatment. Moreover,
the substantial improvements in fatigue observed in
patients during CA treatment give strong support to our
conclusions, which certainly need to be confirmed in a
controlled trial. We therefore recommend that patients
on lenvatinib or vandetanib who experience notable
fatigue should undergo adrenal function testing and that
replacement treatment should be started in those with a
PAI diagnosis, to avoid unwanted TKI discontinuation or
reduction.
Table 2. Urinary Free Cortisol, Morning Salivary Cortisol Levels, and Adrenal Autoantibodies in the Cohort
Morning Salivary
Cortisol (>0.265 mg/dL)
24-h UFC
(17–136 mg/24 h)
Adrenal
Autoantibodies
Response to ACTH Test
(>18 mg/dL) Fatigue (CTCAE 4.03)
1 — 39.5 Negative Impaired Yes
2 0.218 30.9 Negative Impaired Yes
3 0.236 45.2 Negative Impaired Yes
4 0.325 — Negative Normal Yes
5 — 44.3 Negative Normal Yes
6 0.272 — Negative Normal No
7 0.246 — Negative Impaired Yes
8 0.473 47.1 Negative Normal Yes
9 0.241 — Negative Impaired Yes
10 0.364 35.4 Negative Normal Yes
11 0.192 35.7 Negative Impaired Yes
12 0.261 — Negative Normal No
Patients reported in bold have an impaired response to ACTH stimulation test and consistently low morning salivary cortisol levels.
Abbreviation: UFC, urinary free cortisol.
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Figure 2. (A) Degree of fatigue according to the CTCAE (version 4.03) in patients before treatment with CA and at each control after the start
of the replacement therapy. (B) ACTH and cortisol levels during TKI treatment in patients started on CA therapy. The basal evaluation of the
adrenal function was always assessed during the morning (8:00 to 9:00 AM) and in a fasting state.
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